IMPORTANT SAFETY INFORMATION:
NEXAVAR is contraindicated in patients with known severe hypersensitivity to sorafenib or any other component of NEXAVAR. Continue reading below

NEXAVAR in locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine therapy

Progression-free survival (PFS) results

In DECISION, NEXAVAR demonstrated a median PFS of 10.8 months (95% CI, 9.1-12.9) vs 5.8 months (95% CI, 5.3-7.8) with placebo (HR=0.59; 95% CI, 0.46-0.76; P<0.001).1,2

Download Button

DECISION (StuDy of sorafEnib in loCally advanced or metastatIc patientS with radioactive Iodine-refractory thyrOid caNcer) study:
A randomized, double-blind, placebo-controlled, multicenter, Phase III study in patients with locally recurrent or metastatic, progressive,
DTC refractory to RAI (N=417).1,2
HR=hazard ratio; CI=confidence interval.

  • NEXAVAR nearly doubled progression-free survival (PFS)1
  • Death or progression occurred in 113 (55%) of patients in the NEXAVAR arm and 136 (65%) in the placebo arm1

Indications

NEXAVAR is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC).

NEXAVAR is indicated for the treatment of patients with advanced renal cell carcinoma (RCC).

NEXAVAR is indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.

Important Safety Information

For important risk and use information about NEXAVAR, please see the full Prescribing Information.

INDICATION and IMPORTANT SAFETY INFORMATION for STIVARGA® (regorafenib)

For important risk and use information about STIVARGA, please see the full Prescribing Information including the Boxed Warning.

You are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

REFERENCES:

1. NEXAVAR Prescribing Information. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc. 2. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319-328.